Publications

The Lancet. Oncology

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

01-12-2018

Molecular oncology

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

01-11-2018

European journal of cancer (Oxford, England : 1990)

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

01-10-2018

European journal of cancer (Oxford, England : 1990)

Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012.

01-09-2018

BMC cancer

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.

24-07-2018

Annals of surgery

Response to: "DCIS and Breast Cancer: Challenging the Paradigm".

01-07-2018

Genes

Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.

17-05-2018

Annals of surgery

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

01-05-2018

Breast cancer research and treatment

Enrichment of high-grade tumors in breast cancer gene expression studies.

01-04-2018

BMC cancer

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.

27-02-2018

PloS one

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.

22-12-2017

Nature genetics

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.

01-12-2017

BMJ open

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

14-11-2017

Breast cancer research and treatment

The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study.

01-11-2017

Annals of surgical oncology

Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.

01-11-2017

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

20-08-2017

Journal of the National Cancer Institute

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.

01-08-2017

Nature genetics

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

01-08-2017

Breast cancer research and treatment

MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.

01-07-2017

Cancer imaging : the official publication of the International Cancer Imaging Society

Additional value of ¹⁸F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

25-05-2017

PloS one

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

23-05-2017

Critical reviews in oncology/hematology

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.

01-04-2017

Breast cancer research : BCR

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

09-03-2017

European journal of cancer (Oxford, England : 1990)

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

01-03-2017

Clinical cancer research : an official journal of the American Association for Cancer Research

BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.

01-03-2017

Breast (Edinburgh, Scotland)

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

01-02-2017

Breast cancer research and treatment

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

01-01-2017

Journal of the National Cancer Institute

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

01-11-2016

Breast cancer research : BCR

Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

18-10-2016

Breast cancer research and treatment

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

01-10-2016

Virchows Archiv : an international journal of pathology

An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.

01-09-2016

Breast cancer research : BCR

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

05-08-2016

Investigative radiology

Prediction Model For Extensive Ductal Carcinoma In Situ Around Early-Stage Invasive Breast Cancer.

01-07-2016

Oncotarget

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

07-06-2016

AJR. American journal of roentgenology

Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT.

01-06-2016

Breast cancer research : BCR

The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.

10-05-2016

Nederlands tijdschrift voor geneeskunde

[Ductal carcinoma in situ: the balance between over- and undertreatment].

14-04-2016

Breast cancer research and treatment

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.

01-04-2016

Breast cancer research and treatment

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.

01-04-2016

Virchows Archiv : an international journal of pathology

Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.

01-04-2016

Clinical nuclear medicine

Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer.

01-04-2016

Nature

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.

25-02-2016

Breast cancer research : BCR

Genetic predisposition to ductal carcinoma in situ of the breast.

17-02-2016

Scientific reports

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

05-01-2016

Molecular cancer therapeutics

High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.

01-01-2016

Breast cancer research and treatment

Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.

01-11-2015

Breast cancer research : BCR

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

03-10-2015

European journal of cancer (Oxford, England : 1990)

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.

01-08-2015

Breast cancer research and treatment

Fat/water ratios measured with diffuse reflectance spectroscopy to detect breast tumor boundaries.

01-08-2015

Breast cancer research and treatment

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

01-08-2015